Kidney International Reports · Oct 1, 2026

Cardiovascular Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies in Patients with CKD

By Naim MAAZ, Thomas F, Streja E et al.

INTRODUCTION: In patients with chronic kidney disease (CKD), atherogenic lipid profiles, characterized by hypertriglyceridemia and impaired high-density lipoprotein cholesterol (HDL-C) metabolism, contribute to adverse cardiovascular disease (CVD) outcomes. Since evidence on CVD outcomes of triglyceride-targeting lipid-lowering therapies (LLTs), such as fibrates and niacin, remains limited, kidney disease guidelines recommend further investigation. METHODS: We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US Veterans to identify 46,904 patients with incident CKD initiating de novo fibrate, niacin, or statin therapy. We compared the risk of major adverse cardiovascular events (MACE; composite of acute myocardial infarction, ischemic stroke, congestive heart failure, or all-cause death) using Cox proportional hazards models adjusted for baseline covariates during follow-up of up to 10 years. RESULTS: 16,191 patients (event rate, 79.2; 95% confidence interval [CI], 78.0-80.4 per 1000 person-years) experienced MACE after a median follow-up of 3.70 years. The risk of MACE was significantly lower (hazard ratio [HR], 0.93 [95% CI, 0.86-0.99]; P = 0.03) in de novo fibrate users compared with statin users. Niacin users, however, did not have a significantly different risk of MACE (1.03 [0.95-1.12]; P = 0.42) than statin users. The result was largely attributable to the association between fibrate use and congestive heart failure (CHF)-a statistically significant 13% lower hazard (0.87 [0.78-0.96]; P = 0.005) compared with statin use. CONCLUSION: In this large nationwide cohort of patients with nonkidney replacement therapy-dependent CKD, de novo fibrate use, but not niacin use, was associated with a lower risk of MACE than de novo statin use.

doi.org/10.1016/j.ekir.2026.107116Open accessPubMed 43022087Interventions

AgingResearch.News